Dynavax Technologies Corp. (NASDAQ:DVAX) was up 2.4% during trading on Wednesday . The stock traded as high as $17.50 and last traded at $17.26, with a volume of 267,115 shares trading hands. The stock had previously closed at $16.85.

Several equities research analysts have recently issued reports on DVAX shares. Cowen and Company restated a “buy” rating and set a $60.00 price target on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Zacks Investment Research upgraded shares of Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. JPMorgan Chase & Co. lowered shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $29.00 to $22.00 in a research note on Wednesday, April 27th. Finally, Royal Bank Of Canada lowered shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $48.00 to $17.00 in a research note on Wednesday, April 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $32.20.

The firm’s market capitalization is $616.34 million. The firm’s 50-day moving average price is $15.50 and its 200-day moving average price is $16.89.

Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.07. During the same quarter in the previous year, the business posted ($0.80) earnings per share. The business earned $2.65 million during the quarter, compared to analysts’ expectations of $1.58 million. The firm’s revenue was up 70.8% on a year-over-year basis. Equities research analysts predict that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Dynavax Technologies Corp. stock. Trexquant Investment LP raised its position in Dynavax Technologies Corp. (NASDAQ:DVAX) by 14.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,200 shares of the biopharmaceutical company’s stock after buying an additional 8,911 shares during the period. Trexquant Investment LP owned about 0.18% of Dynavax Technologies Corp. worth $1,696,000 at the end of the most recent reporting period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.